The biotech firm uses proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder to deliver payloads, such as mRNA or gene editing tools, that can reprogram specific cell types in vivo. Capstan Therapeutics' platform technology has the potential to transform therapies for a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders, where there are unmet or underserved clinical needs. For more information, visit their website at www.capstantx.com.